Ann: Request For Voluntary Suspension extension 7 days, page-106

First 106 Last

Share
Profile

Follow
Ash90

342 Posts.

47

10/05/18

19:45

Post #: 33020491
Share

Originally posted by Basileus ↑

Hmm ... evidence please?

In the interim and while your searching for that which you will not find - I suggest you try reading this.

https://www.asx.com.au/regulation/regulatory-compliance/asx-corporations-act-obligations.htm

You're not a lawyer are you?

Guidance note 12? Seriously, this is kiddies stuff.

Guess what - a guidance note is a guidance note. The Corporations Act is legislation. Hoping I do not have to explain the difference of those two things to you!

And if you read guidance note 12 it refers to "listing rules" as I did in my earlier post. And just for the benefit of others;

https://www.asx.com.au/documents/rules/gn12_changes_to_activities.pdf

"... a whole raft of situations" - that's a very nice way (Alice in Wonderland type nice) to describe the legal role of the ASX within the context of the Corps Act - very technical indeed.

Not much need for ASIC in your world really?

Ok let's get back to my earlier point.

I do not know and I am merely speculating but my money is on these guys and disclosure issues.

The ASX and a "whole raft of situations" - please!

And to the other poster who asked me what I was accusing QBL of now - for your information asking questions is not making accusations - fairly simple English!

Expand

Hi,

are you suggesting that there could possibly be an issue with the listing of QBL as a mining exploration company in relation to the recent acquisition? If so why?

I read the ann as the deal being done and now just complying with the asx.

look forward to you reply.

QBL Price at posting: 4.9¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

IRE

Iress runs 'hot' for Wealth Within's stock tips

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Failure to report prompts ASX to impose multiple company suspensions